vTv Therapeutics to Participate in Upcoming Mizuho, Stifel and Piper Jaffray Conferences

HIGH POINT, N.C.–(BUSINESS WIRE)– vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical
company engaged in the discovery and development of new orally
administered treatments for Alzheimer’s disease and diabetes, today
announced that it will be participating in the following conferences:

• Global Mizuho Investor Conference (MIC) NY on Monday, November
  14 in New York.
• Stifel 2016 Healthcare Conference on Tuesday and Wednesday,
  November 15-16 in New York. vTv’s senior executives will be presenting
  on Tuesday, November 15, from 4:30-5:10 pm in Winslow on the 5^th
  floor.
• Piper Jaffray Healthcare Conference on Tuesday and Wednesday,
  November 29-30 in New York. vTv’s senior executives will be presenting
  on Wednesday, November 30 from 10:30-10:55 am.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer’s disease and type 2 diabetes as well as
treatment of inflammatory disorders and the prevention of muscle
weakness.

The company’s Alzheimer’s disease drug candidate, azeliragon,
is a novel oral small molecule antagonist of the Receptor for Advance
Glycation Endproducts (RAGE) with first-in-class potential.

The azeliragon development program has been granted Fast Track
Designation and agreement on its Phase 3 protocol has been reached with
FDA via a Special Protocol Assessment (SPA). Enrollment of part A of the
Phase 3 STEADFAST study in patients with mild Alzheimer’s disease was
completed during the third quarter and topline data from this part of
the study is anticipated to be reported in early 2018.

vTv is also pursuing the clinical development of TTP399, a novel liver
selective Glucokinase Activator (GKA) with first-in-class potential for
the treatment of type 2 diabetes. The company recently announced
positive top line results from the six month phase 2b AGATA Study in
subjects with type 2 diabetes.

vTv’s second diabetes drug candidate, TTP273, is an oral, small molecule
GLP-1R agonist with best-in-class potential. The company reported the
completion of enrollment of the three month Phase 2 LOGRA study in the
third quarter with data readout expected at the end of 2016. The
previous Phase 1b trial of TTP273 demonstrated robust effects on
postprandial and fasting glucose. All doses of TTP273 were well
tolerated with no serious adverse events or evidence of gastrointestinal
side effects compared to placebo.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks
and uncertainties. These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and, in each case, their negative or other various or comparable
terminology. All statements other than statements of historical facts
contained in this release, including statements regarding the timing of
our clinical trials, our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements.
These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause our results to vary from
expectations include those described under the heading “Risk Factors” in
our Annual Report on Form 10-K and our other filings with the SEC. These
forward-looking statements reflect our views with respect to future
events as of the date of this release and are based on assumptions and
subject to risks and uncertainties. Given these uncertainties, you
should not place undue reliance on these forward-looking statements.
These forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law, we
undertake no obligation to update or review publicly any forward-looking
statements, whether as a result of new information, future events or
otherwise after the date of this release. We anticipate that subsequent
events and developments will cause our views to change. Our
forward-looking statements do not reflect the potential impact of any
future acquisitions, merger, dispositions, joint ventures or investments
we may undertake. We qualify all of our forward-looking statements by
these cautionary statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161110006371/en/